CME Information

Title: Earlier Treatment of Invasive Fungal Infections: Are We There Yet?

 

RELEASE DATE: 2/16/2013
EXPIRATION DATE: 2/15/2014
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 1.5 Hours

 

MEDIA: Interactive presentation

 

Statement of Need

 

While early diagnosis and initiation of appropriate antifungal therapy are crucial to assure optimal outcomes for patients with invasive mycoses, there are many barriers to early, effective management. Better screening methods and newer diagnostic techniques, when effectively employed, should enable more rapid and accurate diagnoses of these challenging infections. Furthermore, appropriate use of current and emerging antifungals with enhanced antifungal spectra should also afford better outcomes despite changing epidemiologic trends and the emergence of resistant pathogens. This educational activity—Earlier Treatment of Invasive Fungal Infections: Are We There Yet?—challenges the audience to assess whether we are now in an era in which appropriate diagnostics and therapeutics can be employed early in the management of invasive mycoses to improve antifungal outcomes. The initiative uses case-based learning and a panel-discussion format to address the current status of management of aspergillosis, candidiasis, cryptococcal, and endemic fungal infections.

 

Learning Objectives

 

After completing this activity, the participants will be better able to:

  • Define the barriers to early treatment of invasive fungal infections
  • Employ currently available and emerging diagnostics for invasive fungal infections, thus assuring the earliest diagnosis possible
  • Choose appropriate therapies for early management of invasive fungal infections

Target Audience

 

This activity is directed to infectious disease physicians, hematologists/oncologists, critical care physicians, transplant physicians, pathologists, and other healthcare providers responsible for the management of invasive mycoses.

 

Accreditation

 

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure Policy

 

It is the policy of the UNMC Center for Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in this activity are expected to disclose to the audience any financial interest or other relationship he/she has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.

 

Faculty Disclosures

 

Peter G. Pappas, MD, FACP

RESEARCH SUPPORT: Astellas Pharma US; Merck & Co; Pfizer, Inc; T-2 Biosystems
ADVISORY BOARD: Astellas; Merck & Co; T-2 Biosystems

INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: New therapeutics for invasive mycoses, including isavuconazole, ravuconazole

 

Thomas F. Patterson, MD, FACP, FIDSA

GRANT SUPPORT/RESEARCH/DATA COMMITTEE REVIEW: Astellas Pharma US; Merck & Co; Pfizer, Inc.; Associates of Cape Cod; Bio Rad
CONSULTANT: Astellas Pharma US; Merck & Co; Pfizer, Inc.

 

Jose A. Vazquez, MD, FACP, FIDSA

RESEARCH/GRANT SUPPORT: Astellas Pharma US; Merck & Co; Pfizer, Inc.
SPEAKER: Astellas Pharma US; Pfizer, Inc.

 

Nelesh Govender, MBBCh, MMed, FCPath(SA)

No conflicts to disclose.

 

George Thompson, MD, FACP

INVESTIGATOR-INITIATED RESEARCH GRANTS: Astellas Pharma US; Pfizer, Inc.
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: Off-label therapies for coccidioidomycosis

 

Paul Verweij, MD, PhD

RESEARCH/GRANT SUPPORT: Astellas; Gilead Sciences; Merck & Co; Pfizer, Inc.
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: Off-label therapies for aspergillosis

 

Planning Committee Disclosures

 

Lois Colburn

No conflicts to disclose.

 

Alison Freifeld, MD

No conflicts to disclose.

 

Brenda C. Ram, CMP

No conflicts to disclose.

 

Lisa A. Tushla, PHD, H(ASCP)

No conflicts to disclose.

 

System Requirements

 

To participate, you will need access to a computer (either MAC or PC) with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web broswer or an Internet Explorer (version 8.0 or greater) web browser, Javascript enabled, connected to the Internet (high speed connection preferred).

 

Internet Privacy Information

 

UNMC, The MSG Education & Research Consortium and Terranova Medica respect your privacy. We don't share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission.

 

For more information about privacy online, cookies, and what a Web server can and cannot learn about you without your cooperation, visit the Center for Democracy and Technology's Privacy page at: http://www.cdt.org/privacy/.

 

Disclaimers

 

The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the University of Nebraska Medical Center, Center for Continuing, the Mycoses Study Group Educational Committee, and Terranova Medica, LLC.

Healthcare professionals and other individuals should review and consider other publications and materials on the subject before relying solely upon the information contained within this educational activity.

 

Additional Information

 

There is no charge for this activity.

 

This activity is supported by an independent educational grant from Astellas Scientific and Medical Affairs Inc., IMMY, Luminex, MiraVista Diagnostics, T2 Biosystems, and Viracor-IBT.

 

Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component.

 

This event is neither sponsored nor endorsed by the American Society for Microbiology.

 

For further information, contact Tom Davis by telephone (877-276-4523), fax (805-648-8070), or email (tdavis@terranovamedica.com).

 

Copyright © 2012 UNMC CCE, Terranova Medica, LLC; MSG Education & Research Consortium

Sponsored by The University of Nebraska Medical Center, TerraNova Medica, and The MSG Education & Research Consortium
Supported by Educational Grants from: Astellas, IMMY, Luminex, MiraVista Diagnostics, T2 Biosysems, and Viraco IBT

Aspergillus fumigatus image provided courtesy of Dr. David Ellis and the University of Adelaide.
Cryptococcus neoformans image provided courtesy of Gross L (2006) Iron Regulation and an Opportunistic AIDS-Related Fungal Infection. PLoS Biol 4(12): e427. doi:10.1371/journal.pbio.0040427